Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Exclusion Criteria

• •4. Have measurable disease on cross sectional imaging (defined as at least 1 bi-dimensionally measurable nodal lesion ≥1.5 centimeter \[cm\] in the greatest transverse diameter \[GTD\] regardless of the short axis diameter) documented by diagnostic imaging (computed tomography \[CT\], or magnetic resonance imaging \[MRI\]) recorded on or during the 8 weeks prior to index date
• •5. Have been seen at a site that routinely assesses DLBCL treatment response according to Lugano classification of malignant lymphoma (ie, sites with ≥50% DLBCL patients with treatment response according to Lugano classification)
• •6. Have DLBCL treatment response assessed according to Lugano classification of malignant lymphoma or are deceased prior to opportunity for assessment
• •1. Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS non-Hodgkin's lymphoma (NHL) on or prior to index date
• •2. History of allo-stem cell transplant (SCT) prior to index date
• •3. Treatment with any chimeric antigen receptor T (CAR-T) therapy prior to index date
• •4. Received anti-CD20 x anti-CD3 bispecific therapy prior to index date
• •5. History of neurodegenerative condition or CNS movement disorder on or prior to index date
• •6. Evidence of significant cardiovascular disease on or prior to index date
• •7. Evidence of significant pulmonary disease, defined as obstructive pulmonary disease and a history of symptomatic bronchospasm on or prior to index date
• •8. Eastern Cooperative Oncology Group (ECOG) performance status \>1 on or prior to index date
• •9. Inadequate organ function as defined in the protocol